Grants and Giving
Alnylam Pharmaceuticals funds evidence-based educational projects to improve clinical decision-making and patient care in transthyretin-mediated amyloidosis (ATTR-CM).
Funder: Alnylam Pharmaceuticals
Due Dates: May 29, 2026 (Submission deadline for RFP ALNY-RFP-TTR-13)
Funding Amounts: Up to $250,000 per proposal; multiple awards possible; actual award may be less than requested.
Summary: Supports independent educational projects to improve clinical decision-making in transthyretin-mediated amyloidosis (ATTR-CM).
Key Information: Only organizations (not individuals) may apply; ACCME accreditation required for medical education providers.
Description
Alnylam Pharmaceuticals is offering grant support for independent educational initiatives focused on advancing clinical decision-making in transthyretin-mediated amyloidosis (ATTR-CM). This opportunity (RFP ALNY-RFP-TTR-13) seeks proposals that address persistent gaps in screening, diagnosis, monitoring, and management of ATTR-CM, with a strong emphasis on practical, real-world application for healthcare professionals. Supported projects should equip clinicians with actionable tools and frameworks that can be readily implemented in routine practice, ultimately aiming to improve patient outcomes. Funding is available for activities such as symposia, digital education, and live regional programs, and content must be grounded in peer-reviewed evidence, free from commercial bias, and designed for broad dissemination.
